This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
M

ASCO® 2024 Insights: "RAGNAR Trial - Erdafitinib Efficacy & Safety in Advanced NSCLC With FGFR Alterations"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Martin Schuler
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Martin Schuler
117 views
June 6, 2024

Chapters

Erdafitinib in Advanced NSCLC: RAGNAR Trial Insights

00:00

Efficacy & Safety Results: Promising Outcomes

05:59

0 Comments
Login to view comments. Click here to Login

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

2024 ASCO® Annual Meeting Insights Hub: Lung Videos

17:22
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "SCLC Treatment Evolution - Debunking Myths…

Feat. A. Chiang
40:00
ecancer

ASCO® 2024: Highlights and Analysis of Key Solid Cancer Trials

Feat. B. Gyawali
04:26
ecancer

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance vs. Local C…

Feat. P. Iyengar
View All

Related Content

AUTOPLAY
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

35:40
Balazs Halmos

Year in Review: Lung Cancer

57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
27:04
Fengting Yan

Cancer Screening Molecular Tools

36:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Feat. B. Halmos
29:25
Northwestern Medicine Oncology and Hematology

Hyperprogression in Cancer Treated With Immunotherapy

Feat. Y. Chae
02:41
GRACE

Staging Disease: How Oncologists Stage NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang
16:10
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

Feat. L. Raez
11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

Feat. V. Subbiah
25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
14:49
Vivek Subbiah

Year in Review: Precision Medicine

19:33
ecancer

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Feat. E. Felip, A. Spira, A. Passaro, A. Addeo
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
11:45
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxe…

Feat. T. Mok
21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC